ArticleKorean journal of radiology2025
Post-Treatment PET/CT Dosimetry to Predict Contralateral Lobe Hypertrophy After Transarterial Radioembolization for Hepatocellular Carcinoma.
Article in Korean journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveImage-based dosimetry in transarterial radioembolization (TARE) has been proposed for the prediction of contralateral lobe hypertrophy as well as tumor response. This study aimed to evaluate the predictive value of post-treatment ⁹⁰Y PET/CT voxel-based dosimetry for post-TARE liver hypertrophy in treatment-naïve patients with hepatocellular carcinoma (HCC). MATERIALS AND
methodsThis retrospective single-center study included 40 treatment-naïve patients with right lobar HCC (age, 66.4 ± 12.5 years; male:female, 29:11) who underwent TARE with ⁹⁰Y-labeled glass microspheres. Voxel-based absorbed dose maps were generated from ⁹⁰Y PET/CT performed 16-24 hours post-treatment; dose histograms were obtained for the whole liver, right lobe (RL), and non-tumor RL (NRL). Mean absorbed dose and volume proportion receiving ≥50 Gy (P₅₀) and ≥100 Gy (P₁₀₀) for each region were calculated. All patients underwent follow-up CT-2-4 months after treatment, and the percentage increase in left lobe (LL) volume was measured using CT volumetry. The efficacy of dosimetric parameters and conventional clinical factors in predicting LL hypertrophy was analyzed using Spearman's correlation and multivariable regression.
resultsThe median LL volume increase was 12.7% (interquartile range, 5.7%-28.1%). The mean absorbed dose (ρ = 0.662,
conclusionPost-TARE ⁹⁰Y PET/CT dosimetry, particularly in combination with platelet count, is an effective approach to predict contralateral hypertrophy in treatment-naïve patients with HCC. Further studies with larger prospective cohorts are required to validate these predictive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.